BioNTech SE
BNTX
$96.35
-$0.38-0.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.95% | 7.44% | 0.51% | -27.67% | -52.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.95% | 7.44% | 0.51% | -27.67% | -52.12% |
| Cost of Revenue | 17.34% | 26.88% | -0.26% | -9.92% | -19.55% |
| Gross Profit | 5.02% | 3.43% | 0.71% | -30.99% | -55.47% |
| SG&A Expenses | -9.56% | -11.02% | 2.72% | 7.41% | 12.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 298.37% | 323.07% | 243.64% | 238.50% | 174.70% |
| Total Operating Expenses | 16.92% | 17.86% | 49.77% | 63.20% | 34.95% |
| Operating Income | -86.07% | -86.48% | -2,339.61% | -196.36% | -111.61% |
| Income Before Tax | -69.83% | -61.72% | -650.71% | -157.56% | -108.92% |
| Income Tax Expenses | -64.47% | -117.38% | -181.54% | -105.44% | -83.24% |
| Earnings from Continuing Operations | -26.46% | 29.76% | -786.05% | -171.78% | -117.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.46% | 29.76% | -786.05% | -171.78% | -117.67% |
| EBIT | -86.07% | -86.48% | -2,339.61% | -196.36% | -111.61% |
| EBITDA | -72.41% | -105.15% | -598.51% | -170.23% | -106.99% |
| EPS Basic | -26.18% | 29.71% | -772.17% | -172.03% | -117.83% |
| Normalized Basic EPS | -102.56% | -52.09% | -451.17% | -146.86% | -106.13% |
| EPS Diluted | -24.80% | 29.88% | -810.16% | -173.18% | -118.28% |
| Normalized Diluted EPS | -97.03% | -47.68% | -466.27% | -147.62% | -106.39% |
| Average Basic Shares Outstanding | -0.09% | 0.36% | 0.17% | -0.03% | -0.41% |
| Average Diluted Shares Outstanding | -0.53% | 0.16% | -0.03% | -0.47% | -0.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |